🔗 Share this article Users Discontinuing Anti-Obesity Injections Put On Pounds at a Quadrupled Rate Than People Using Diet and Exercise Obesity treatment often requires ongoing approaches. A recent study reveals that individuals who stop using blockbuster weight-loss injections like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who end conventional diet and exercise programs. Published data in a prominent medical journal points out that while obese people often shed substantial amounts of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation. "People buying such medications must be cognizant of the danger of fast weight regain when the therapy concludes," cautioned expert Dr. Susan Jebb. Such speed of regain suggests a reversion to original mass within about a year and a half. Comparing Approaches The analysis, which looked at 37 of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods. Researchers emphasize that individuals who shed pounds through lifestyle changes alone usually experience a more gradual weight regain—around 0.1 kg a month—post-intervention. The Reason for the Rapid Rebound Nutrition scientists propose the mode of action of the injections is key to understanding the heightened regain. GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate appetite. "Long-term administration of the hormone levels several times higher than the body's typical production may cause the system to produce less of its own natural hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert. "Withdrawal of this medication results in appetite is unsuppressed, making excessive eating much more probable." A Chronic Condition? Health authorities advise the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications. Many experts contend that, given the significant potential of relapse, the therapy is often long-term. This opinion is supported by pharmaceutical companies, who state that the results "underscore the persistent character of obesity," akin to managing diseases like high blood pressure. Patient Experiences Users who have stopped the medication report a sudden return of cravings. "It felt as if a trigger that goes on and I was suddenly ravenous," said a patient. This challenge is exacerbated if patients have not developed lasting dietary or behavioural modifications during therapy. Growing Adoption Survey data indicate that a significant number of people in the UK have used these injections in the last 12 months, with demand being substantial. Adoption is higher among women than males. The middle-aged demographic shows the highest level of interest. Many access the medications through private prescriptions rather than public health services. Finally, researchers caution that while the jabs are powerful agents for weight loss, they are not a permanent cure and lasting health benefits likely depends on integrated behavioural management.
Obesity treatment often requires ongoing approaches. A recent study reveals that individuals who stop using blockbuster weight-loss injections like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who end conventional diet and exercise programs. Published data in a prominent medical journal points out that while obese people often shed substantial amounts of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation. "People buying such medications must be cognizant of the danger of fast weight regain when the therapy concludes," cautioned expert Dr. Susan Jebb. Such speed of regain suggests a reversion to original mass within about a year and a half. Comparing Approaches The analysis, which looked at 37 of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods. Researchers emphasize that individuals who shed pounds through lifestyle changes alone usually experience a more gradual weight regain—around 0.1 kg a month—post-intervention. The Reason for the Rapid Rebound Nutrition scientists propose the mode of action of the injections is key to understanding the heightened regain. GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate appetite. "Long-term administration of the hormone levels several times higher than the body's typical production may cause the system to produce less of its own natural hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert. "Withdrawal of this medication results in appetite is unsuppressed, making excessive eating much more probable." A Chronic Condition? Health authorities advise the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications. Many experts contend that, given the significant potential of relapse, the therapy is often long-term. This opinion is supported by pharmaceutical companies, who state that the results "underscore the persistent character of obesity," akin to managing diseases like high blood pressure. Patient Experiences Users who have stopped the medication report a sudden return of cravings. "It felt as if a trigger that goes on and I was suddenly ravenous," said a patient. This challenge is exacerbated if patients have not developed lasting dietary or behavioural modifications during therapy. Growing Adoption Survey data indicate that a significant number of people in the UK have used these injections in the last 12 months, with demand being substantial. Adoption is higher among women than males. The middle-aged demographic shows the highest level of interest. Many access the medications through private prescriptions rather than public health services. Finally, researchers caution that while the jabs are powerful agents for weight loss, they are not a permanent cure and lasting health benefits likely depends on integrated behavioural management.